USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and full-year ended December 29, 2018.
Fourth quarter 2018 net sales were $299.0 million, compared with $273.1 million in the prior-year period, or a 9.5% increase year-over-year. The strengthening of the U.S. dollar negatively impacted net sales by $10.5 million for the quarter. The Company’s total number of active customers increased 9.0% year-over-year to 616,000.
Fourth quarter net earnings were $32.3 million, or $1.32 per diluted share, compared with a net loss of $5.9 million, or $0.24 per share during the prior-year period. The net loss in the prior year period was due to a one-time, non-cash charge of $30.1 million, or $1.24 per diluted share, related to the U.S. tax reform (the “Tax Reform”) enacted on December 22, 2017.
Additionally, costs associated with China and the Company’s internal investigation into its China operations, which was first disclosed in February 2017, negatively impacted fourth quarter 2017 net earnings by approximately $2.7 million and earnings per diluted share by $0.11. Excluding both the impact of the Tax Reform and the expense related to China and the Company’s internal investigation, net earnings increased 20.4%, or $0.21 per diluted share.
“USANA finished the year with another quarter of solid results, bolstered by our annual China National Sales Meeting in Macau and a few targeted product promotions in select markets,”
said Kevin Guest, Chief Executive Officer.
Weighted average diluted shares outstanding were 24.5 million for the fourth quarter of 2018, compared with diluted shares of 24.0 million in the prior-year period. During the quarter, the Company repurchased 682,843 shares of common stock for $79.8 million.
The Company ended the quarter with no debt, $214.3 million in cash and cash equivalents, and $63.5 million invested in short-term securities. As of December 29, 2018, there was $70.2 million remaining under the current share repurchase authorization.
Net sales in the Asia Pacific region increased by 12.2% to $243.3 million for the fourth quarter of 2018. The total number of active customers in the Asia Pacific region increased by 14.1% year-over-year. Within Asia Pacific, net sales increased:
- 14.1% in Greater China;
- 25.3% in North Asia; and
- 3.3% in Southeast Asia Pacific.
Sales growth in Greater China was primarily driven by 17.4% active customer growth in Mainland China, while sales growth in North Asia resulted from 19.4% active customer growth in South Korea. Sales growth in Southeast Asia Pacific was driven by 21.9% active customer growth in the Philippines.
Net sales in the Americas and Europe region decreased by 1.1% to $55.8 million for the fourth quarter of 2018, primarily due to a 6.5% decrease in active customers.
“We continued to generate strong local currency growth across most of our markets during the fourth quarter, despite an unfavorable impact from currency exchange rates,” continued Mr. Guest.
Net sales for fiscal 2018 increased by 13.6% to $1.189 billion, compared with $1.047 billion in 2017. Changes in foreign currency exchange rates positively impacted net sales by $12.2 million. On a constant currency basis, net sales increased by 12.4% during fiscal 2018.
Net earnings for 2018 increased by 101.8% to $126.2 million, or $5.12 per diluted share, compared with $62.5 million, or $2.53 per diluted share in the prior year. Net earnings in 2017 were reduced by a one-time, non-cash charge of $30.1 million, or $1.22 per diluted share, related to the Tax Reform.
In addition, costs related to China and the Company’s internal investigation into its China operations in 2017 totaling $7.6 million after tax negatively impacted earnings per diluted share by $0.31. Excluding both the impact of the Tax Reform and the expense related to China and the internal investigation, 2018 net earnings improved by 26.8%, or $1.10 per diluted share. Weighted average diluted shares outstanding were 24.6 million for the full year 2018, compared with 24.7 million in the prior-year period.
Mr. Guest added,
“Fiscal 2018 marks the 16th consecutive year that USANA has delivered record sales. Leverage generated from this exceptional sales growth produced stronger than anticipated operating margins and the highest net earnings in the history of the Company. Outside of our financial performance, we accomplished several meaningful initiatives that generated momentum and better positioned us for continued growth into the future. Notably, Celavive® generated approximately $38 million in incremental sales in 2018, growing skincare sales to 9.0% of net sales in the fourth quarter.
“We also made significant progress in improving our global IT infrastructure, particularly in China where we launched several improvements to enhance our customer’s experience, that we believe contributed to our active customer growth during the year. In 2019, we will continue to focus on growing our customer base by further improving the speed, convenience, and ease of doing business with USANA,” concluded Mr. Guest.
USANA (NYSE:USNA) prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative new skincare line, USANA has proven for more than 25 years why it’s a company you can trust. How about giving us a try? Shop at USANA.com or learn more at whatsupusana.com.
Get more information, facts and figures about USANA, click here for the USANA overview.